(S)-V-0219

Cat. No.: HY-143312C

Molecular Formula: $C_{20}H_{25}F_3N_4O_2$

Molecular Weight: 410.43

Target: GLP Receptor

Pathway: GPCR/G Protein

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	(S)-V-0219 is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (S)-V-0219 activates calcium fluxes in HEK cells stably expressing hGLP-1R. (S)-V-0219 is orally active and ameliorates high glucose levels in mice and inhibits feeding behavior in fasted mice[1].
IC_{50} & Target	GLP-1R[1]
In Vitro	(S)-V-0219 ((S)-9) (0.1 nM) potentiates calcium fluxes in HEK cells stably expressing hGLP-1R[1]. (S)-V-0219 (0.1 nM) potentiates insulin secretion stimulated by GLP-1 in the stable human pancreatic cell line EndoC-βH1 under high glucose concentration[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	(S)-V-0219 ((S)-9) (0.04-0.2 mg/kg; i.p.) improves glucose handling after injection of 2 g/kg glucose in normal male Wistar rats [1]. (S)-V-0219 (0. 4 mg/kg; i.g.) is orally active in fatty diabetic Zucker rats[1]. (S)-V-0219 (0.1-5 μg/kg in 5 μL; i.c.v.) decreases feeding in 12-h fasted male Wistar rats[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Decara JM, et, al. Discovery of V-0219: A Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor toward Oral Treatment for "Diabesity". J Med Chem. 2022 Apr 14;65(7):5449-5461.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA